

Announcement Summary

Entity name

APIAM ANIMAL HEALTH LIMITED

Announcement Type

New announcement

Date of this announcement

26/5/2022

The Proposed issue is:

C An accelerated offer

Total number of +securities proposed to be issued for an accelerated offer

ASX +security code	+Security description	Maximum Number of +securities to be issued
АНХ	ORDINARY FULLY PAID	28,924,553

Trading resumes on an ex-entitlement basis (ex date) 30/5/2022

+Record date

30/5/2022

Offer closing date for retail +security holders

17/6/2022

Issue date for retail +security holders

24/6/2022

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

APIAM ANIMAL HEALTH LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

50604961024

1.3 ASX issuer code

AHX

1.4 The announcement is ☑ New announcement

1.5 Date of this announcement

26/5/2022

1.6 The Proposed issue is:

An accelerated offer

1.6b The proposed accelerated offer is

Accelerated non-renounceable entitlement offer (commonly known as a JUMBO or ANREO)

Proposed issue of securities



Part 3 - Details of proposed entitlement offer issue

Part 3A - Conditions

3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis?

🕑 No

Part 3B - Offer details

Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued

ASX +security code and description

AHX : ORDINARY FULLY PAID

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? ✓ Existing class Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

ASX +security code and description

AHX : ORDINARY FULLY PAID

ISIN Code (if Issuer is a foreign company and +securities are non CDIs)

ISIN Code for the entitlement or right to participate in the offer (if Issuer is foreign company and +securities are non CDIs)

Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)

Has the offer ratio been determined? ☑ Yes

The quantity of additional +securities For a given quantity of +securities



to be issued	held
5	24

What will be done with fractional entitlements?	Maximum number of +securities proposed to be issued (subject to rounding)
Fractions rounded up to the next whole number	28,924,553

Offer price details for retail security holders

Has the offer price for the retail offer been determined? $\ensuremath{\mathfrak{C}}$ Yes

In what currency will the offer be made?	What is the offer price per +security for the retail offer?
AUD - Australian Dollar	AUD 0.70000

Offer price details for institutional security holders

Has the offer price for the institutional offer been determined? $\ensuremath{\mathfrak{C}}$ Yes

In what currency will the offer be made?	What is the offer price per +security for the institutional offer?
	AUD 0.70000

AUD - Australian Dollar

Oversubscription & Scale back details

Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)? ⓒ No

Will a scale back be applied if the offer is over-subscribed? $\textcircled{\sc S}$ No

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? ☑ Yes

Part 3D - Timetable

3D.1a First day of trading halt

26/5/2022



3D.1b Announcement date of accelerated offer

26/5/2022

3D.2 Trading resumes on an ex-entitlement basis (ex date)

30/5/2022

3D.5 Date offer will be made to eligible institutional +security holders

27/5/2022

3D.6 Application closing date for institutional +security holders

27/5/2022

3D.8 Announcement of results of institutional offer (The announcement should be made before the resumption of trading following the trading halt) 30/5/2022

3D.9 +Record date

30/5/2022

3D.10a Settlement date of new +securities issued under institutional entitlement offer

2/6/2022

3D.10b +Issue date for institutional +security holders

2/6/2022

3D.10c Normal trading of new +securities issued under institutional entitlement offer

3/6/2022

3D.11 Date on which offer documents will be sent to retail +security holders entitled to participate in the +pro rata issue

2/6/2022

3D.12 Offer closing date for retail +security holders

17/6/2022

3D.13 Last day to extend retail offer close date

14/6/2022

3D.19 +Issue date for retail +security holders and last day for entity to announce results of retail offer

24/6/2022



Part 3E - Fees and expenses

3E.1a Who is the lead manager/broker?

Shaw and Partners Limited and Morgans Corporate Limited.

3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

The Joint Lead Managers will be paid in their respective proportions:

- a selling fee of 2% of the offer proceeds; and
- a management fee of 3% of the offer proceeds.

The Joint Lead Managers will not be paid a selling fee or management fee proceeds received from the Directors of the Company, management and key staff of the Company, under the Institutional Entitlement Offer

3E.2 Is the proposed offer to be underwritten?

🕑 Yes

3E.2a Who are the underwriter(s)?

Shaw and Partners Limited and Morgans Corporate Limited.

3E.2b What is the extent of the underwriting (ie the amount or proportion of the offer that is underwritten)?

100%

3E.2c What fees, commissions or other consideration are payable to them for acting as underwriter(s)?

The Underwriters will be paid in their respective proportions, an underwriting fee of 1% of the offer proceeds.

3E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated

Relevant details are set out in the Capital Raising announcement dated 26 May 2022.

3E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer? S No

3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer Standard share registry, external advisers and ASX administrative fees.

Part 3F - Further Information

3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

The funds raised will be used to fund further acquisitions and to reduce debt.



3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue?

🕑 No

3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful? S No

3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue

All countries other than Australia and New Zealand

3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities

🕑 Yes

3F.5a Please provide further details of the offer to eligible beneficiaries

The Retail Entitlement Offer will be made available to nominees with a registered address in Australia or New Zealand who were registered as a holder of Shares at the Record Date and who held those Shares on behalf of underlying beneficial holders who reside in Australia or New Zealand.

3F.6 URL on the entity's website where investors can download information about the proposed issue

https://www.apiam.com.au/investor-portal/

3F.7 Any other information the entity wishes to provide about the proposed issue

N/A

3F.8 Will the offer of rights under the rights issue be made under a disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)? Statement No